Abstract Fibronectin (FN) fragments found in chronic inflammatory diseases, including periodontal disease and arthritis, may contribute to tissue destruction in part via induction of matrix metalloproteinases (MMPs). We previously showed that the 120-kDa FN fragment containing the central cell binding domain (120FN) dose dependently induces MMP-1 (collagenase-1) in human periodontal ligament (PDL) cells, whereas intact FN did not elicit this response. Recently, we found that an increase in MMP-1 expression is accompanied by a decreased osteoblastic phenotype in PDL cells. We hypothesized that 120FN inhibits osteoblastic differentiation of PDL cells by inducing MMP-1. Effects of increasing concentrations of 120FN on MMP-1 expression and on osteoblastic markers were assessed in cultured PDL cells using Western blotting, qRT-PCR, and collagen degradation and alkaline phosphatase (AP) activity assays. The 120FN dose dependently increased MMP-1 expression and activity, concomitant with a decrease in AP activity. The increase in collagenase activity was largely attributed to increased MMP-1 expression. Concurrent with the decrease in AP activity, the 120FN reduced baseline and dexamethasoneinduced gene expression of specific osteoblastic markers, Runx2 and osteonectin, and diminished mineralized nodule formation. Finally, siRNA inhibition of 120FN-induced MMP-1 reduced collagenase expression and rescued the AP phenotype to baseline levels. These findings suggest that disease-associated 120FN, in addition to having direct effects on tissue destruction by upregulating MMPs, could contribute to disease progression by impeding osteoblastic differentiation of osteogenic PDL cells and, consequently, diminish bone regeneration.
Abstract Fibronectin (FN) fragments found in chronic inflammatory diseases, including periodontal disease and arthritis, may contribute to tissue destruction in part via induction of matrix metalloproteinases (MMPs). We previously showed that the 120-kDa FN fragment containing the central cell binding domain (120FN) dose dependently induces MMP-1 (collagenase-1) in human periodontal ligament (PDL) cells, whereas intact FN did not elicit this response. Recently, we found that an increase in MMP-1 expression is accompanied by a decreased osteoblastic phenotype in PDL cells. We hypothesized that 120FN inhibits osteoblastic differentiation of PDL cells by inducing MMP-1. Effects of increasing concentrations of 120FN on MMP-1 expression and on osteoblastic markers were assessed in cultured PDL cells using Western blotting, qRT-PCR, and collagen degradation and alkaline phosphatase (AP) activity assays. The 120FN dose dependently increased MMP-1 expression and activity, concomitant with a decrease in AP activity. The increase in collagenase activity was largely attributed to increased MMP-1 expression. Concurrent with the decrease in AP activity, the 120FN reduced baseline and dexamethasoneinduced gene expression of specific osteoblastic markers, Runx2 and osteonectin, and diminished mineralized nodule formation. Finally, siRNA inhibition of 120FN-induced MMP-1 reduced collagenase expression and rescued the AP phenotype to baseline levels. These findings suggest that disease-associated 120FN, in addition to having direct effects on tissue destruction by upregulating MMPs, could contribute to disease progression by impeding osteoblastic differentiation of osteogenic PDL cells and, consequently, diminish bone regeneration. Chronic inflammatory diseases such as periodontal disease are initiated by micro-organisms and perpetuated by systemic and local host responses to these agents resulting in the loss of bone. These micro-organisms and by-products of their action initiate an inflammatory process that enhances the expression of proteolytic enzymes, which lead to the dissolution of protein components into fragments. The proteolysis of matrix macromolecules generates bioactive fragments that in turn may accentuate the disease process. Fragments generated from the proteolysis of fibronectin (FN) are key contributors to this process.
FN is a large multifunctional glycoprotein present in the extracellular matrix (ECM) of many tissues including the periodontium. It contains multiple domains that bind collagen, heparin, fibrin, and cells [1] [2] [3] [4] . The regions between these domains are highly susceptible to proteolysis. Proteolysis, typically present at sites of inflammation, including periodontitis, arthritis, metastatic processes and injury, leads to the generation of FN fragments [5] [6] [7] [8] [9] . These proteolytic fragments, which contain functional domains, mediate activities that are not induced by intact FN [10] [11] [12] [13] . Thus, for example, several FN fragments have been implicated in cartilage degradation in arthritis, and synovial fluid containing these fragments stimulates chondrocyte-mediated cartilage matrix degradation, presumably through induction of matrix metalloproteinases (MMPs) [13] [14] [15] . In vitro, these fragments also induce specific MMPs in synovial fibroblasts [10] fibrocartilaginous cells [14, 16] and periodontal ligament (PDL) cells [11] .
Several FN fragments, including a 120-kDa fragment (120FN) containing the central cell-binding domain (CCBD), have been found in association with chronic inflammatory periodontal disease [7, 8, 17, 18] . The 120 FN, which is a by-product of proteolysis of FN, has been found at concentrations of up to 1 lM in gingival crevicular fluid of patients with periodontitis and in synovial fluid of patients with arthritis [7, 9] . This FN fragment therefore is common to both these chronic inflammatory disorders and may modulate disease pathogenesis or progression through various pathways including the induction of matrix metalloproteinases (MMPs), including MMP-1 in PDL cells [11] and synoviocytes [9] .
The basis by which the 120FN-induced MMPs contribute to disease progression and bone breakdown is not known, but it may include their ability for direct degradation of the collagenous matrices and the facilitation of subsequent dissolution of the mineralized components of bone by osteoclasts [19] . Furthermore, on the basis of findings showing that increased levels of endogenous and exogenous collagenases inhibit osteoblastic differentiation of osteogenic cells including PDL cells [20] [21] [22] [23] [24] , it is plausible that upregulation of collagenases by 120FN may delay or inhibit osteoblastic differentiation of PDL cells, thereby diminishing the pool of cells available for bone repair and regeneration. Although the 120FN induces the collagenolytic MMP-1 in PDL cells [11] and MMP-1 directly inhibits osteoblast differentiation of PDL cells [22, 24] , there is currently no evidence that the 120FN-enhanced expression of endogenous MMP-1 undermines the osteoblastic differentiation of these cells. Therefore, the purpose of this study was to determine the direct effects of 120FN-induced MMP-1 in regulating the osteoblastic phenotype of PDL cells. PDL cells are a heterogeneous population of multipotential cells that can undergo osteoblastic differentiation and mineralized nodule formation [25] [26] [27] [28] and are essential to bone homeostasis in vivo. The findings of this study may provide insights into the mechanisms by which disease-associated FN fragments contribute to the perpetuation of bone loss or inhibition of bone regeneration in periodontitis and other inflammatory diseases.
Materials and Methods

Preparation and Purification of the 120-kDa Fibronectin Fragment
Chymotryptic digestion of fibronectin and subsequent purification were undertaken as previously described [29] with some modifications. Briefly human plasma fibronectin (Millipore, Billerica, MA) was digested with a-chymotrypsin (5 U enzyme/mg FN; Sigma-Aldrich, St. Louis, MO) for 1 h 10 min at 37°C. The reaction was stopped by the addition of diphenyl carbomyl chloride (Sigma-Aldrich). The digested FN was subjected to gelatin-Sepharose affinity chromatography (Gelatin-Sepharose 4B; GE Healthcare Bioscience Corp., Piscataway, NJ) to remove gelatin-binding fragments, and the subsequent flow-through was chromatographed on heparin-Sepharose (Heparin-Sepharose 6 Fast Flow; Healthcare Bioscience Corp.) to remove heparinbinding fragments. The next flow-through, containing primarily a 120-kDa fragment, was pooled, dialyzed against water, and concentrated using a 100-kDa molecular weight cutoff filter (Amicon Ultra-100 filter device; Millipore, Billerica, MA). At each of these steps, the FN digests were characterized or the purity of the 120FN was analyzed by electrophoresis on 10% SDS-PAGE gels followed by Coomassie blue staining. The final purified product was confirmed to be the 120-kDa CCBD of FN by Western blotting. The concentration of 120FN was determined by Bradford microassay (Bio-Rad, Hercules, CA) according to the manufacturer's instructions.
Periodontal Ligament Cell Culture
Primary human PDL cells were isolated from teeth extracted for orthodontic reasons or for therapeutic third molar extraction under IRB approval as previously described [11] . Cells were grown in a-MEM medium supplemented with 10% fetal bovine serum, 1% penicillin/ streptomycin, and 1% fungizone. Cells from the third through the sixth passage were used for all experiments. Cells were cultured in serum-free medium (a-MEM supplemented with 0.2% lactalbumin hydrolysate [LAH] ) to eliminate the complex effects of serum on cell responses. Cells were rinsed again after 6 h and cultured in serum-free medium with or without the 120FN (0.001-0.1 lM) for various time points.
For transfection with MMP-1 siRNA, the PDL cells were plated at 30,000/cm 2 in a-MEM with 10% FBS and incubated for 24 h. Cells were transfected with 100 pmol/ well of siRNA to MMP-1 or nonsense siRNA (Stealth RNAi Negative Control; Invitrogen Corp., Carlsbad, CA) using Lipofectamin2000 and Opti-MEM (Invitrogen). After 24 h, cells were washed and serum-free medium (with 0.2% LAH) without or with 120FN (0.1 lM) was added. After 3 days of culture the cell-conditioned medium was collected for MMP assays. Cells were counted and lysed in distilled water for AP assay. Total RNA was extracted for quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) analysis for Runx2, osteonectin (ON), and MMP-1.
For mineralization experiments, cells were cultured in FN-depleted low-serum (1%) medium containing ascorbic acid and b-glycerophosphate without or with 120FN (0.1 lM). The medium was changed every third day. Serum FN was depleted by passing FBS through a heparinSepharose column [30, 31] . Experiments were terminated after 14 days, and the cells fixed for von Kossa staining [32] .
FITC-Collagen Degradation Assay
Total collagenase activity in conditioned medium was assessed by an FITC-collagen degradation assay as described previously [24] . A 96-well plate was coated with FITC-collagen (15 lg/ml; Chondrex, Redmond, WA, USA) overnight at 4°C and washed twice with PBS. Cellconditioned medium (100 ll) was added to the wells, and the mixture incubated at 37°C for 1 h. The fluorescence intensity of degraded collagen products was determined with a microplate spectrofluorometer (Spectramax M2; Molecular Devices, Sunnyvale, CA) with excitation at 494 nm and emission at 518 nm. As a reference, 100 ll of blank medium containing 3000 ng of bacterial collagenase was added to one set of wells for complete digestion of FITC-collagen. Data were converted to relative fluorescence units (RFU) of collagenase activity as described by the manufacturer and standardized to the total protein in the medium.
Substrate Zymography
Gelatin substrate zymography was used to detect and characterize proteinase activity in PDL cell-conditioned medium. Cell-conditioned medium (20 ll) was mixed with 49 sample buffer and electrophoretically resolved in 10% SDS-PAGE gels containing 2 mg/ml gelatin (E1A grade; Bio-Rad) as described previously [11] . Following electrophoresis, SDS was removed by washing the gels in 2.5% Triton X-100. Then gels were placed in incubation buffer at 37°C for 24 h, stained with 0.5% Coomassie blue, and destained until proteinase bands were clearly visible.
Western Immunoblotting
Western blots using standard methods were performed to determine the modulation of MMP-1 in conditioned medium by 120FN and MMP-1 siRNA or to characterize the purity of FN fragments. Equal volumes (20 ll) of conditioned medium were electrophoretically resolved on 10% SDS-PAGE gels, and the proteins transferred to PVDF membranes. Nonspecific binding was blocked with 5% dry nonfat milk in Tris-buffered saline with 0.1% Tween 20 (TBST) for 1 h, and membranes were washed twice with TBST and incubated for 3 h with rabbit anti-human MMP-1 or CCBD of FN primary antibodies (Chemicon International Inc., Temecula, CA, USA). After further washes with TBST, membranes were incubated with a 1:1000 dilution of a peroxidase-conjugated goat anti-rabbit antibody (Sigma-Aldrich) in TBST for 1 h. Membranes were washed again and the protein bands were visualized using enhanced chemiluminescence (Super Signal West Pico, Pierce, Rockford, IL).
Alkaline Phosphatase Activity Assay AP activity was assayed in cell lysates by enzymatic conversion of p-nitrophenylphosphate (p-NT) substrate to p-nitrophenol (Sigma-Aldrich) as described previously [32] . The amount of p-nitrophenol produced was measured spectrophotometrically at a wavelength of 410 nm, quantified against a standard curve (nM), and the results standardized by cell number per minute.
Quantitative Reverse Transcriptase-Polymerase Chain Reaction MMP-1, Runx2, ON, and GAPDH mRNA levels were assayed by qRT-PCR after 72 h of 120FN treatment. A time course (18-, 36-, and 72-h) quantification for MMP-1 mRNA was also performed. Total RNA was extracted using the RNeasy Mini Kit (Qiagen Corp., Valencia, CA) according to the manufacturer's instructions. Reverse transcription was performed on 50 ng total RNA in the initial mix with M-MLV reverse transcriptase according to the manufacturer's instructions (SuperScript III; Invitrogen). All primers and probes (GAPDH, cat. no. Hs 99999905_m1; MMP-1, cat. no. Hs 00233958_m1; Runx2, cat. no. Hs 00231692_m1; ON, cat. no. Hs 00277762_m1) were obtained commercially (TaqManGene Expression Assay; Applied Biosystems, Foster City, CA) and RNAs amplified per the manufacturer's instructions (TaqManUniversal PCR Master Mix; Applied Biosytems). Amplification was done under the following conditions: 50°C for 2 min, 95°C for 10 min, followed by 40 cycles of 94°C for 15 s and 60°C for 1 min. Data were analyzed using the ABI Prism 7500 SDS 1.2 Software (Applied Biosystems).
Von Kossa Staining
Cells were fixed in 100% ethanol, rehydrated in a graded ethanol series, washed, incubated in 5% silver nitrate for 1 h at 37°C, and exposed to bright light for 10 min. Mineralized nodules were examined under a microscope and quantified by video densitometry [32] . A total of six different fields were counted for each well and the mean ± SD of mineralized nodules per well was calculated.
Statistical Analysis
The results are expressed as mean (±SD) fold change in collagenase levels or activity or osteoblast marker gene levels over control baseline levels for a minimum of three experiments, each performed in triplicate. Data were analyzed by a two-way ANOVA followed by a post hoc Fisher's PLSD test, with the level of significance set at P \ 0.05. The relationship between the fold change in AP activity and the collagenase activity was determined by a Pearson's correlation analysis.
Results
Purification of 120FN
Assay of human plasma FN digests with a-chymotrypsin revealed a multitude of protein fragments (Fig. 1a) , which, when subjected to successive fractionation through gelatinSepharose columns, resulted in partial purification of 120 FN in addition to several other fragments (Fig. 1b) . Subsequent elution through a heparin-Sepharose column produced relatively purified 120FN and several lower molecular weight fragments (Fig. 1c) . Dialysis of this eluate using a 100-kDa centrifugation filter resulted in a purified 120FN (Fig. 1d) , which was identified as the 120-kDa CCBD of FN (Fig. 1e) by Western blot using an antibody specific to this domain.
120FN Dose-and Time-Dependently Increases Collagenase Expression While Concomitantly Decreasing AP Activity in PDL Cells
In order to determine the concentration of 120FN that produces maximal effects on MMP-1 expression and activity in PDL cells for use in subsequent experiments, we first performed 120FN dose-response experiments. The 120FN dose-dependently induced a 53/58-kDa gelatinolytic proteinase (Fig. 2a) . This proteinase was identified as MMP-1 by Western blots, which also confirmed its dosedependent induction by 120FN (Fig. 2b) . Further confirmation of 120FN's dose-dependent modulation of MMP-1 was provided by qRT-PCR, which showed a significant induction of MMP-1 mRNA at the two highest concentrations of the fragment (Fig. 2c) . In contrast to the dosedependent induction of MMP-1 protein and mRNA by 120FN, collagenase and AP activity were significantly modulated only at a 0.1 lM concentration of 120FN (Fig. 2d, e) . The contrasting findings of enhanced MMP-1 expression but no increase in collagenase activity at 0.01 lM 120FN may result from a concomitant but differential induction of MMP inhibitors at different concentrations of the 120FN and/or due to MMP-1 activation being modulated only at higher concentrations of 120FN [11] .
Because 0.1 lM 120FN produced significant increases in MMP-1 expression and collagenase activity, we next utilized this concentration of 120FN to determine its timedependent induction of collagenase and its potential modulation of AP activity in PDL cells. Cells incubated with 0.1 lM 120FN exhibited increasing expression of MMP-1 protein levels (Fig. 3a, b) , gene levels (Fig. 3c) , and collagenase activity (Fig. 3d) over time. This increase in collagenase activity and MMP-1 mRNA was significant (P \ 0.05) at 36 and 72 h of culture, relative to control untreated cells and to levels at the beginning of the experiment. In contrast, while control cells demonstrated increasing levels of AP activity at 36 and 72 h of culture, cells cultured with 120FN maintained the AP phenotype at control levels over time ( qRT-PCR (c) and collagenase activity analyzed by FITC-collagen degradation assay on cell-conditioned medium (d). Assays on cell extract revealed that, relative to control untreated cells, 120FN inhibits the time-dependent increase in AP activity (e). Data are shown as mean (±SD) fold change relative to control baseline levels (Ct) for three experiments performed in triplicate. * P \ 0.05; ** P \ 0.01; *** P \ 0.001 significant effects on collagenase and AP activities at 72 h, we used this concentration of the fragment and this time point for subsequent experiments.
Induction of MMP-1 by 120FN Is Accompanied by Inhibition of the Expression of Osteoblast-Specific Markers
To examine further the role of 120FN in modulating osteoblast differentiation in PDL cells, we assessed its effects on osteoblast-specific markers, Runx2 and ON, by qRT-PCR as well as AP activity. Cells cultured in proosteogenic dexamethasone were used as positive controls. As demonstrated in previous experiments and studies, 0.1 lM 120FN enhanced, while dexamethasone repressed, collagenase activity (Fig. 4a) and MMP-1 gene expression (Fig. 4b) [24] . Dexamethasone's repression of collagenase was accompanied by a significant increase in AP activity (130%), Runx2 (40%), and ON (20%) gene expression relative to control cells (Fig. 4c-e) . In contrast, the induction of collagenase activity and MMP-1 gene expression by 120FN was accompanied by a significant suppression of AP activity (70%), as well as Runx2 (23%) and ON (58%) gene expression, relative to untreated cells.
120FN-Mediated Suppression of Alkaline Phosphatase Activity Is Specifically Mediated Through MMP-1
Evidence that the 120FN inhibits osteoblastic differentiation by inducing MMP-1 expression was sought by specifically inhibiting MMP-1 with siRNA in the presence and absence of this fragment. Western blotting confirmed successful silencing of MMP-1 with siRNA and its induction by 120FN (Fig. 5a) . Furthermore, the induction of MMP-1 by 120FN was largely suppressed in the presence of MMP-1 siRNA. These effects of 120FN and MMP-1 siRNA on collagenase activity mimicked that of their effects on MMP-1 expression (Fig. 5b) . The changes in collagenase levels and activity were accompanied by an inverse regulation of AP activity (Fig. 5c) . Specifically, 120FN's induction of MMP-1 was paralleled by a decrease in the AP phenotype of the cells, while the suppression of constitutive MMP-1 expression was accompanied by increased AP activity. Finally, the suppression of 120FN-induced MMP-1 by siRNA rescued the AP phenotype similar to that in control untreated PDL cells. This finding confirms the contribution of 120FN-enhanced MMP-1 in modulating AP in PDL cells.
The 120FN Decreases Mineralized Nodule Formation by PDL Cells Under Osteogenic and Mineralizing Conditions
Finally, we examined the effects of 120FN on the deposition of mineralized matrix by PDL cells in the absence and presence of pro-osteogenic and mineralizing conditions. As expected and as shown previously [32, 33] mineralized nodule formation was significantly enhanced (P \ 0.001) in cells treated with b-glycerophosphate and ascorbic acid relative to cells cultured in control medium (Fig. 6a, b) . bGlycerophosphate and ascorbic acid produced significantly greater mineralized nodule formation even in cells cultured 
Discussion
We previously demonstrated a strong negative relationship between repression of MMP-1 expression and activity by dexamethasone and induction of several osteoblastic markers including AP, osteocalcin, and ON in PDL cells [24, 32] . We further demonstrated an inverse relationship between collagenase and AP activities using both chemical inhibitors of MMPs and MMP-1 siRNA [22, 24] . In longterm cultures, the dexamethasone-mediated decrease in collagenase expression and enhanced osteoblastic markers was accompanied by a significant increase in mineralized nodule formation in dexamethasone-treated versus control cells [32] . Conversely, overexpression or addition of exogenous MMP-1 results in an inhibition of most osteoblast markers in osteogenic PDL cells [22] . Together these studies suggest an important contribution of collagenolytic MMPs in regulating osteoblastic differentiation of PDL cells. The findings of the current study extend these previous observations [22, 24] by showing that osteoblastic differentiation can be inhibited even when endogenous MMP-1 expression is secondarily enhanced by bioactive agents such as 120FN that are commonly found in association with chronic inflammatory conditions. Our findings show a consistent inverse relationship between disease-associated 120FN-induced MMP-1 levels and osteoblastic markers in PDL cells, and demonstrate that 120FN inhibits osteoblastic differentiation and mineralization of PDL cells specifically by inducing MMP-1 expression in these cells. In addition to these effects of 120FN on osteoblastogenesis, these findings may also offer insights into the basis for previous observations for the repression of osteoblastic differentiation by proinflammatory cytokines such as interleukin (IL)-1b [21] . In these studies, it was noted that treatment of PDL cells with IL-1b suppressed the expression of osteoblast markers even under osteogenic conditions. Although this inhibition of osteoblastic differentiation was accompanied by increases in collagenase levels, a direct cause-and-effect relationship between IL-1b-induced collagenase and osteoblast differentiation was not determined. Our studies provide the first evidence of a link between exogenously stimulated MMP-1 expression and repression of osteoblastic phenotype in osteogenic cells.
Although MMPs induced by pro-inflammatory cytokines have been found in association with inflammatory disorders including periodontal disease and arthritis and implicated in tissue destruction, our study provides the first evidence of a different mechanism by which these agents and MMPs may exacerbate tissue degeneration. Inhibition of osteoblastic differentiation by FN fragments and other collagenase inducing agents could eventually lead to a diminished pool of osteoblasts and a subsequent decrease in bone formation and reparative capacity of the tissue. Taken together these data suggest that FN fragments may perpetuate periodontal disease by increasing net bone loss through induction of specific MMPs, which in turn leads to disturbances in the osteogenic capacity of the cells. Thus, the current data suggest a novel mechanism for bone remodeling mediated by disease-associated FN fragments and outline factors important in maintaining equilibrium between bone formation and bone resorption in preserving healthy periodontal tissues. Identification of such regulatory pathways provides new insights into the pathogenesis of periodontal disease and chronic inflammation, which may point to potential avenues for therapeutic intervention.
The MMP-1 inductive capacity of the 120FN resides in peptide V, an eight-amino acid sequence in region III-14 of FN, which lacks the RGD sequence located in region III-10 of FN [10] . Therefore, it is highly likely that osteoblast differentiation of PDL cells is indirectly regulated by peptide V. Although the basis by which collagenase mediates the inhibition of osteoblast differentiation are not currently known, it may involve one or more possible mechanisms. These include MMP-mediated changes to the stable collagenous matrix [20, 21, 24] , which may modify the cues provided to the cells including those from altered collagenintegrin interactions [34] [35] [36] [37] [38] [39] . Additionally, MMPs may modulate changes in the bioavailability of matrix-bound bioactive agents through the release of matrix-bound growth factors into solution or activate latent bioactive agents [40] [41] [42] . Of these mechanisms, there is substantial evidence that the collagen-initiated signals responsible for osteoblast differentiation are mediated via integrins. These studies have implicated a2-and b1-containing integrins in modulating osteoblast differentiation [35, 36, 38, 39] . In the context of our findings on the effects of 120FN-induced MMP-1 in modulating osteoblastic differentiation, it is conceivable that degradation of collagen disrupts this collagen-integrin signaling, leading to delay or attenuation of osteoblastic differentiation. In contrast, inhibition of MMP-1 may allow faster and more substantial accumulation of collagen [22] , leading to earlier and enhanced differentiation of osteogenic cells into osteoblasts via this collagenintegrin cascade.
